IM Cannabis (NASDAQ:IMCC – Get Free Report) and ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.
Profitability
This table compares IM Cannabis and ANI Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| ANI Pharmaceuticals | 11.07% | 27.37% | 10.47% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for IM Cannabis and ANI Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| ANI Pharmaceuticals | 0 | 4 | 5 | 0 | 2.56 |
Insider & Institutional Ownership
7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
IM Cannabis has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Valuation and Earnings
This table compares IM Cannabis and ANI Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
| ANI Pharmaceuticals | $883.37 million | 1.88 | $78.34 million | $4.64 | 15.54 |
ANI Pharmaceuticals has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats IM Cannabis on 13 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
